Roshan Bastani

Roshan Bastani

Auto-generated profile, based on publicly available information

Roshan Bastani

University of California, Los Angeles (UCLA), Los Angeles, USA

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
RBRoshan Bastani
Roshan Bastani
BGBeth A. Glenn
Beth A. Glenn
JTJennifer Tsui
Jennifer Tsui
LCL. Cindy Chang
L. Cindy Chang
EMErica J. Marchand
Erica J. Marchand
RSRita Singhal
Rita Singhal
Background: The introduction of human papillomavirus (HPV) vaccines represents a breakthrough in the primary prevention of cervical cancer. However, little is known about vaccination uptake and correlates among low-income, ethnic minority, and immigrant populations in the U.S. who may benefit most from the vaccine. Methods: Telephone interviews (N = 490) were conducted in six languages between January and November 2009 among mothers of vaccine-eligible girls (ages 9–18) using the Los Angeles County Department of Public Health, Office of Women's Health service referral hotline. HPV and vaccine awareness, knowledge, beliefs, barriers, and daughter's vaccine receipt were assessed. Results: The sample consisted of low-income, uninsured, ethnic minority, and immigrant women. Only 29% of daughters initiated the vaccine and 11% received all three doses. No ethnic differences were observed in initiation or completion rates. Ethnic differences were observed in HPV awareness, perceived risk, and other vaccine-related beliefs. The strongest predictor of initiation was vaccine awareness (OR = 12.00). Daughter's age and reporting a younger acceptable age for vaccination were positively associated with initiation. Mothers of unvaccinated girls reported lacking information about the vaccine to make a decision (66%) and not knowing where they could obtain the vaccine (74%). Conclusion: Vaccination rates in this sample were lower than state and national estimates, and were associated with low levels of vaccine awareness. Interventions, including culturally targeted messaging, may be helpful for enhancing HPV–vaccine knowledge, modifying vaccine-related beliefs and increasing uptake. Impact: Our findings provide valuable guidance for developing interventions to address suboptimal HPV vaccination in high-risk groups. Cancer Epidemiol Biomarkers Prev; 20(7); 1463–72. ©2011 AACR.

1 January 2010 in Preventive Medicine
Verified
Journal Article
Closed access
RBRoshan Bastani
Roshan Bastani
BGBeth A. Glenn
Beth A. Glenn
VTVicky M. Taylor
Vicky M. Taylor
MCMoon S. Chen
Moon S. Chen
TNTung T. Nguyen
Tung T. Nguyen
AMAnnette E. Maxwell
Annette E. Maxwell

6 August 2004 in Cancer
Verified
Journal Article
Open access
PDF file
RBRoshan Bastani
Roshan Bastani
KYK. Robin Yabroff
K. Robin Yabroff
RMRonald E. Myers
Ronald E. Myers
BGBeth Glenn
Beth Glenn
The potential reduction in morbidity and mortality through cancer screening cannot be realized without receipt of appropriate follow‐up care for abnormalities identified via screening. In this paper, the authors critically examine the existing literature on correlates of receipt of appropriate follow‐up care for screen‐detected abnormalities, as well as the literature on interventions designed to increase rates of receipt of follow‐up care. Lessons learned describe what is known and not known about factors that are related to or predict receipt of follow‐up care. Similarly, effective interventions to increase follow‐up are described and gaps identified. A conceptual model is developed that categorizes the health care system in the United States as comprising four levels: policy, practice, provider, and patient. Some patient‐level factors that influence follow‐up receipt are identified, but the lack of data severely limit the understanding of provider, practice, and policy‐level correlates. The majority of intervention studies to increase follow‐up receipt have focused on patient‐level factors and have targeted follow‐up of abnormal Papanicolaou smears. Insufficient information is available regarding the effectiveness of provider, practice, or policy‐level interventions. Standard definitions of what constitutes appropriate follow‐up are lacking, which severely limit comparability of findings across studies. The validity of various methods of obtaining outcome data has not been clearly established. More research is needed on interventions targeting provider, system, and policy‐level factors, particularly interventions focusing on follow‐up of colorectal and breast abnormalities. Standardization of definitions and measures is needed to facilitate comparisons across studies. Cancer 2004. Published 2004 by the American Cancer Society.

1 November 1999 in Preventive Medicine
Verified
Journal Article
Closed access
RBRoshan Bastani
Roshan Bastani
AMAnnette E. Maxwell
Annette E. Maxwell
CBClarence Bradford
Clarence Bradford
IDIrene Prabhu Das
Irene Prabhu Das
KYKang X. Yan
Kang X. Yan

18 March 2021 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
YFYvonne N. Flores
Yvonne N. Flores
GDGeetanjali D. Datta
Geetanjali D. Datta
LYLiu Yang
Liu Yang
ECEdgar Corona
Edgar Corona
DDDivya Devineni
Divya Devineni
FMFolasade P. May
Folasade P. May
Background: Liver cancer is one of the most rapidly increasing cancers in the United States, and hepatocellular carcinoma (HCC) is its most common form. Disease burden and risk factors differ by sex and race/ethnicity, but a comprehensive analysis of disparities by socioeconomic status (SES) is lacking. We examined the relative impact of race/ethnicity, sex, and SES on HCC incidence, stage, and survival. Methods: We used Surveillance, Epidemiology, and End Results (SEER) 18 data to identify histologically confirmed cases of HCC diagnosed between January 1, 2000 and December 31, 2015. We calculated age-adjusted HCC incidence, stage at diagnosis (local, regional, distant, unstaged), and 5-year survival, by race/ethnicity, SES and sex, using SEER*Stat version 8.3.5. Results: We identified 45,789 cases of HCC. Incidence was highest among low-SES Asian/Pacific Islanders (API; 12.1) and lowest in high-SES Whites (3.2). Incidence was significantly higher among those with low-SES compared with high-SES for each racial/ethnic group (P < 0.001), except American Indian/Alaska Natives (AI/AN). High-SES API had the highest percentage of HCC diagnosed at the local stage. Of all race/ethnicities, Blacks had the highest proportion of distant stage disease in the low- and high-SES groups. Survival was greater in all high-SES racial/ethnic groups compared with low-SES (P < 0.001), except among AI/ANs. Black, low-SES males had the lowest 5-year survival. Conclusions: With few exceptions, HCC incidence, distant stage at diagnosis, and poor survival were highest among the low-SES groups for all race/ethnicities in this national sample. Impact: HCC prevention and control efforts should target low SES populations, in addition to specific racial/ethnic groups.

22 November 2016 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
TTTimothy R. Tangherlini
Timothy R. Tangherlini
VRVwani Roychowdhury
Vwani Roychowdhury
BGBeth Glenn
Beth Glenn
CCCatherine M Crespi
Catherine M Crespi
RBRoja Bandari
Roja Bandari
RBRoshan Bastani
Roshan Bastani
A multidisciplinary journal that focuses on public health and technology, public health informatics, mass media campaigns, surveillance, and innovation in public health practice and research. Also dedicated to rapid open data sharing during epidemics.